Tofacitinib, a JAK1/3 Inhibitor As Treatment for Linear IgA Bullous Dermatosis: A Case Report

Dermatitis®Vol. 34, No. 2 LettersTofacitinib, a JAK1/3 Inhibitor As Treatment for Linear IgA Bullous Dermatosis: A Case ReportBirao Fan and Mingyue WangBirao FanDepartment of Dermatology, Peking University First Hospital, Beijing, ChinaNational Clinical Research Center for Skin and Immune Diseases, Beijing, ChinaBeijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, ChinaSearch for more papers by this author and Mingyue WangE-mail Address: wangmy@pku.edu.cnDepartment of Dermatology, Peking University First Hospital, Xishiku Street, Xicheng District, Beijing 100034, ChinaNational Clinical Research Center for Skin and Immune Diseases, Beijing, ChinaBeijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, ChinaSearch for more papers by this authorPublished Online:16 Mar 2023https://doi.org/10.1089/derm.2022.29007.bfaAboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 34Issue 2Apr 2023 Information© 2023 American Contact Dermatitis Society. All Rights Reserved.To cite this article:Birao Fan and Mingyue Wang.Tofacitinib, a JAK1/3 Inhibitor As Treatment for Linear IgA Bullous Dermatosis: A Case Report.Dermatitis®.Apr 2023.160-161.http://doi.org/10.1089/derm.2022.29007.bfaPublished in Volume: 34 Issue 2: March 16, 2023Online Ahead of Print:January 19, 2023PDF download